{"id":"W2536552580","doi":"10.1007/s11060-016-2288-5","title":"NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma","year":2016,"lang":"en","type":"article","venue":"Journal of Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"National Institutes of Health; National Cancer Institute; NRG Oncology; Wellcome Trust","keywords":"Temozolomide; Irinotecan; Bevacizumab; Glioblastoma; Medicine; Oncology; Internal medicine; Randomized controlled trial; Chemotherapy; Cancer; Colorectal cancer; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019702,0.001821479,0.002492446,0.0007553613,0.000426358,0.001432144,0.001333489,0.001342304,0.007692039],"category_scores_gemma":[0.001541258,0.0008371422,0.001767371,0.0006001607,0.001418446,0.001340015,0.0005284481,0.003426131,0.001378571],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001646677,"about_ca_system_score_gemma":0.002287425,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003134229,"about_ca_topic_score_gemma":0.009306372,"domain_scores_codex":[0.9993494,0.0003380242,0.00003382946,0.000115499,0.00004298025,0.0001202191],"domain_scores_gemma":[0.9993692,0.0001061743,0.0001308833,0.00004066909,0.00002221234,0.0003309019],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9431173,0.01107264,0.0007725189,0.0005132424,0.001227488,0.00005242893,0.000112036,0.001304472,0.004675229,0.0003246634,0.002733281,0.03409464],"study_design_scores_gemma":[0.9102849,0.08520666,0.001542518,0.00003017405,0.0005222226,0.00004575292,0.0000408218,0.0006447752,0.0004909557,0.0001822537,0.0009844741,0.0000245564],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901757,0.002974037,0.0004380211,0.0007548528,0.0004851948,0.00194451,0.0007766519,0.0001749836,0.002276003],"genre_scores_gemma":[0.9882619,0.002146608,0.001431949,0.001022085,0.0002893879,0.00196937,0.001303496,0.00004439922,0.003530901],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007692039,"threshold_uncertainty_score":0.02573246,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03050901912674331,"score_gpt":0.350022182008827,"score_spread":0.3195131628820837,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}